Have a feature idea you'd love to see implemented?
Let us know!
RVMD Revolution Medicines Inc
Price (delayed)
$56.78
Market cap
$9.55B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.66
Enterprise value
$9.43B
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities
Highlights
The company's equity has surged by 87% YoY but it fell by 3.2% QoQ
RVMD's quick ratio is up by 47% year-on-year but it is down by 7% since the previous quarter
The revenue has dropped by 97% year-on-year
The gross profit has dropped by 97% year-on-year
Key stats
What are the main financial stats of RVMD
Market
Valuations
Earnings
Shares outstanding
168.22M
Market cap
$9.55B
Enterprise value
$9.43B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.06
Price to sales (P/S)
12,767.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12,714.36
Revenue
$742,000
EBIT
-$566.42M
EBITDA
-$555.12M
Free cash flow
-$551.11M
Per share
Balance sheet
Liquidity
EPS
-$3.66
Free cash flow per share
-$3.3
Book value per share
$9.38
Revenue per share
$0
TBVPS
$10.14
Total assets
$1.76B
Total liabilities
$196.7M
Debt
$86.71M
Equity
$1.57B
Working capital
$1.47B
Debt to equity
0.06
Current ratio
14.24
Quick ratio
14
Net debt/EBITDA
0.21
Margins
Efficiency
Dividend
EBITDA margin
-74,814%
Gross margin
100%
Net margin
-76,423.3%
Operating margin
-88,031.9%
Return on assets
-30.1%
Return on equity
-33.7%
Return on invested capital
-39.9%
Return on capital employed
-34.3%
Return on sales
-76,336.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RVMD stock price
How has the Revolution Medicines stock price performed over time
Intraday
-0.51%
1 week
-1.03%
1 month
18.91%
1 year
173.11%
YTD
97.98%
QTD
25.2%
Financial performance
How have Revolution Medicines's revenue and profit performed over time
Revenue
$742,000
Gross profit
$742,000
Operating income
-$653.2M
Net income
-$567.06M
Gross margin
100%
Net margin
-76,423.3%
The revenue has dropped by 97% year-on-year
The gross profit has dropped by 97% year-on-year
RVMD's operating income has dropped by 77% year-on-year and by 9% since the previous quarter
Revolution Medicines's net income has plunged by 71% YoY and by 9% from the previous quarter
Growth
What is Revolution Medicines's growth rate over time
Valuation
What is Revolution Medicines stock price valuation
P/E
N/A
P/B
6.06
P/S
12,767.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12,714.36
The EPS has declined by 13% year-on-year
The company's equity has surged by 87% YoY but it fell by 3.2% QoQ
The P/B is 78% higher than the last 4 quarters average of 3.4 and 73% higher than the 5-year quarterly average of 3.5
The stock's price to sales (P/S) is 152% more than its last 4 quarters average of 5069.5
The revenue has dropped by 97% year-on-year
Efficiency
How efficient is Revolution Medicines business performance
RVMD's ROIC is up by 32% year-on-year and by 10% since the previous quarter
Revolution Medicines's return on equity has increased by 13% YoY and by 2.6% QoQ
RVMD's ROA is up by 10% YoY
The return on sales has declined by 8% since the previous quarter
Dividends
What is RVMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RVMD.
Financial health
How did Revolution Medicines financials performed over time
RVMD's total assets has soared by 79% year-on-year but it is down by 2.5% since the previous quarter
Revolution Medicines's current ratio has increased by 48% YoY but it has decreased by 8% from the previous quarter
The debt is 94% less than the equity
The company's equity has surged by 87% YoY but it fell by 3.2% QoQ
The debt has grown by 38% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.